α-N-acetylgalactosaminidase Levels in Panic Disorder

This prospective observational cohort study investigated serum α-N-acetylgalactosaminidase levels in drug-naïve patients with Panic Disorder (PD) at baseline and after six weeks of follow-up and compared them with healthy controls (HC). Associations between enzyme levels, symptom severity, and inflammatory markers were examined. The study aimed to evaluate whether α-N-acetylgalactosaminidase levels are associated with PD symptom severity and inflammatory parameters.

NCT Number	NCT07424911
Lead Sponsor	Elazığ Mental Health and Diseases Hospital
Conditions	Panic Disorder
Enrollment	66 participants
Start Date	2025-05-01
Primary Completion	2025-06-16 (estimated)
Study Completion	2025-08-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-29